News · Healthcare market research
SÃO PAULO — 30 May 2026
BioNixus Expands Latin America Presence with São Paulo Office Opening in Q2 2026
New Brazil hub strengthens quantitative and qualitative pharmaceutical research, market access intelligence, and launch support across LATAM for global life sciences teams.
BioNixus, a healthcare and pharmaceutical market research firm, today announced plans to further strengthen and expand its services across Latin America (LATAM) with a new office in São Paulo, Brazil, scheduled to open in Q2 2026. The expansion gives international and regional life sciences clients local fieldwork capacity, faster access to Brazilian payer and regulatory context, and continuity with BioNixus programmes already delivered in the United States, Canada, EMEA, and the GCC.
Brazil is one of the largest pharmaceutical markets in the Americas. Sponsors entering or scaling in the country routinely need evidence aligned with ANVISA registration pathways, CONITEC and public-system reimbursement deliberations, and the distinct dynamics of public (SUS) and private (ANS) coverage. The São Paulo hub will support those decisions with the same governance applied to global BioNixus programmes: quantitative physician and specialist research, qualitative KOL and advisory work, competitive and market-sizing intelligence, and market access strategy linked to launch planning. Teams can align early thinking with the Brazil healthcare market briefing and the wider healthcare market research hub.
“LATAM is a primary growth engine for many of our clients—not a secondary market,” said Laura McConaughey, Research Director at BioNixus. “Opening in São Paulo in Q2 2026 lets us pair deep local execution with the cross-market comparability teams expect when they run US, European, and GCC studies in parallel. Our goal is decision-ready evidence on international quality standards, with Brazilian regulatory and access nuance built in from the first protocol.”
Expanded services in LATAM
BioNixus’ strengthened LATAM offer includes quantitative healthcare research (physician, specialist, and hospital surveys with bilingual fieldwork); qualitative insights (KOL mapping, advisory boards, and interviews across oncology, metabolic, cardiovascular, and other therapy areas); market access and payer intelligence (ANVISA and reimbursement landscaping, HTA-oriented evidence planning, and launch sequencing); market intelligence (therapy-area and country briefings with competitive landscaping); and integrated launch support linking field insights to commercial, medical affairs, and access workstreams.
The São Paulo office will coordinate multi-country LATAM programmes with BioNixus’ existing Americas and EMEA hubs so sponsors retain one methodology owner and harmonised reporting.
Why Brazil, why now
Demand has increased for programmes that combine US and EU governance with LATAM execution speed. Brazil’s scale, complex reimbursement environment, and concentration of clinical and commercial expertise make São Paulo a natural regional anchor. BioNixus expects to confirm inauguration details closer to the Q2 2026 opening. Media and partners may register interest via the BioNixus press contact page.
For partnership enquiries, visit BioNixus contact or the media kit.